| Issue | Title | |
| Vol 2019, No 10 (2019) | Takeda Bolsters IBD Pipeline by Partnering with Prometheus Biosciences | Abstract pdf html |
| Subham Nandi | ||
| Vol 2012, No 11 (2012) | Takeda Bolsters its CNS Pipeline with Envoy Therapeutics Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 10 (2012) | Takeda Boosts Global Vaccine Business with LigoCyte Pharmaceuticals Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2021, No 11 (2021) | Takeda Broadens Gene Therapy Portfolio with Poseida’s Non-Viral Technologies | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2019, No 12 (2019) | Takeda Buys into Viral Immunology with US$1 B Turnstone Deal | Abstract pdf html |
| Michelle Liu | ||
| Vol 2002, No 25 (2002) | Takeda Chemical Industries, Ltd. | Abstract pdf |
| Business Review Editor | ||
| Vol 2021, No 3 (2021) | Takeda Continues Divestment Spree with US$1.3 B Teijin Pharma Deal to Reduce Debt | Abstract pdf html |
| Michelle Liu | ||
| Vol 2016, No 2 (2016) | Takeda Demonstrates Long-term Commitment to Antibody Drug Conjugates in Oncology With its Expanded Agreement With Mersana Therapeutics | Abstract pdf html |
| Natasha Berry | ||
| Vol 2022, No 1 (2022) | Takeda Exercises Option to Acquire Adaptate Biotherapeutics | Abstract pdf html |
| Sasha Yachu | ||
| Vol 2020, No 3 (2020) | Takeda Exercises Option to Acquire PvP Biologics | Abstract html pdf |
| Michelle Liu | ||
| Vol 2011, No 5 (2011) | Takeda Goes Global with US$13.7 B Nycomed Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 5 (2013) | Takeda Joins the Dengue Vaccine Race with Inviragen Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2022, No 7 (2022) | Takeda Licenses F-star’s Immuno-oncology Bispecific Antibody Technology | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2012, No 4 (2012) | Takeda Looks to Offset Revenue Losses with Bolt-On Acquisition of URL Pharma | Abstract |
| Heather Cartwright | ||
| Vol 2016, No 11 (2016) | Takeda Partners with Crescendo Biologics for Humabody®-based Oncology Therapeutics | Abstract pdf html |
| Natasha Berry | ||
| Vol 2019, No 8 (2019) | Takeda Partners with Sosei Heptares on GPCR Targets | Abstract pdf html |
| Michelle Liu | ||
| Vol 2024, No 5 (2024) | Takeda Pays US$100 M Upfront for AC Immune’s Alzheimer’s Vaccine | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2009, No 5 (2009) | Takeda Powers Ahead in Oncology | Abstract |
| Taskin Ahmed | ||
| Vol 2010, No 4 (2010) | Takeda Sets Eyes to Globally Market AMAG’s Anemia Drug | Abstract |
| PharmaDeals Analyst | ||
| Vol 2023, No 2 (2023) | Takeda Signs US$1.13 B Deal with Hutchmed for Colorectal Cancer Drug | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2022, No 4 (2022) | Takeda Signs US$400 M+ Gene Therapy Pact with Evozyne | Abstract html pdf |
| Lucy Haggerty | ||
| Vol 2025, No 3 (2025) | Takeda Signs US$816 M Collaboration with BridGene Biosciences for Small Molecule Drugs | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2008, No 94 (2008) | Takeda Strengthens Foothold in US | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2012, No 1 (2012) | Takeda to Gain Selective PI3K and mTOR Inhibitors via Intellikine Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 54 (2004) | Takeda to Market Sucampo’s Constipation Drug | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 5 (2018) | Takeda Ventures into the Realm of Big Pharma with US$62 B Shire Buyout | Abstract pdf |
| Heather Cartwright & Natasha Piper | ||
| Vol 2019, No 5 (2019) | Takeda’s Deleveraging Begins with Ethicon and Novartis Deals | Abstract pdf html |
| Michelle Liu | ||
| Vol 2018, No 1 (2018) | Takeda’s Strengthens Pipeline with TiGenix and Denali Deals | Abstract pdf html |
| Jasmine Kalsi | ||
| Vol 2006, No 78 (2006) | Tanox Strikes Gold with Genentech Alliance | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 59 (2005) | Tanox to Buy Sunol Tissue Factor Assets | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 55 (2005) | Tarceva (erlotinib) | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 87 (2007) | Targacept and GSK: Power and Paradigms | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 83 (2007) | Technology Focus - Drug Discovery in Fragments | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 79 (2007) | Technology Focus: Antibodies - End of the Boom? | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 37 (2003) | Technology Focus: Antisense | Abstract |
| Business Review Editor | ||
| Vol 2005, No 57 (2005) | Technology Focus: Cell Therapy | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 73 (2006) | Technology Focus: DNA Microarrays | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 27 (2002) | Technology Focus: Gene Therapy | Abstract |
| Business Review Editor | ||
| Vol 2006, No 69 (2006) | Technology Focus: Influenza Diagnostics | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 88 (2007) | Technology Focus: New Frontiers in Transdermal Drug Delivery Systems | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 31 (2002) | Technology Focus: PEGylation | Abstract |
| Business Review Editor | ||
| Vol 2002, No 26 (2002) | Technology Focus: Pharmacogenomics | Abstract |
| Business Review Editor | ||
| Vol 2003, No 32 (2003) | Technology Focus: Stem Cells | Abstract |
| Business Review Editor | ||
| Vol 2006, No 75 (2006) | Telbivudine | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 28 (2002) | Testing for Genetic Variation | Abstract |
| Business Review Editor | ||
| Vol 2014, No 8 (2014) | Teva Advances Pain Management Strategy with Labrys Biologics Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 5 (2011) | Teva Agrees to Acquire Taiyo to Become Key Generics Player in Japan | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 100 (2008) | Teva and Kowa to Create Leading Generics Business in Japan | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2011, No 4 (2011) | Teva and Procter & Gamble Form Joint Venture to Accelerate OTC Drug Sales | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 42 (2003) | Teva Breaks into Injectable Generics with its US$3.4 B Acquisition of SICOR | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 10 (2017) | Teva Divests Women’s Health Portfolio in a Move to Reduce Debt | Abstract pdf html |
| Natasha Piper | ||
| Vol 2015, No 8 (2015) | Teva Drops Mylan Bid with US$40.5 B Acquisition of Allergan Generics | Abstract pdf html |
| Heather Cartwright & Smita Mishra | ||
| Vol 2013, No 7 (2013) | Teva Expands Respiratory Pipeline with MicroDose Therapeutx Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 1 (2013) | Teva Forms Joint Venture with Handok Pharmaceuticals to Tap South Korean Market | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 9 (2011) | Teva Invests in Cocrystal Discovery to Strengthen Speciality Pipeline with Antiviral Therapies | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 103 (2008) | Teva Invests in Yeast-based Drug Discovery Technology | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2012, No 12 (2012) | Teva Licenses Xenon Pharmaceuticals’ Pain Drug XEN402 as Part of New Strategic Plan | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 5 (2011) | Teva Looks to Diversify its Branded Drugs Portfolio with US$6.8 B Cephalon Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2014, No 2 (2014) | Teva Outbids Endo to Secure NuPathe Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2015, No 5 (2015) | Teva Returns to M&A with US$3.5 B Auspex Pharma Purchase Before Making US$40 B Approach for Mylan | Abstract |
| Heather Cartwright & Sayani Datta | ||
| Vol 2008, No 98 (2008) | Teva Strengthens its Position in the US and Spanish Markets | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2016, No 10 (2016) | Teva Tries its Luck with Risky NGF Inhibitor Class by Partnering with Regeneron | Abstract pdf html |
| Jawala Prasad | ||
| Vol 2002, No 25 (2002) | Teva-Tuteur to market Immunomedics’ diagnostic products in Latin America | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 1 (2009) | Teva’s Biosimilar Capabilities Mount with its Latest Joint Venture | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2007, No 85 (2007) | The Bioterrorism Threat: Smallpox Vaccine Stockpiling | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 2 (2014) | The Carlyle Group Offers US$4.15 B for J&J’s Ortho-Clinical Diagnostics | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 88 (2007) | The CEO's Balancing Act | Abstract html |
| Fintan Walton | ||
| Vol 2006, No 69 (2006) | The Changing Face of Indian Pharma | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 74 (2006) | The Culture of Deal Making | Abstract html |
| Fintan Walton | ||
| Vol 2002, No 30 (2002) | The Erectile Dysfunction market | Abstract |
| Business Review Editor | ||
| Vol 2003, No 35 (2003) | The Genome, Predisposition and Personalized Medicine | Abstract |
| Business Review Editor | ||
| Vol 2006, No 70 (2006) | The Impact of Clinical Risk | Abstract html |
| Fintan Walton | ||
| Vol 2008, No 101 (2008) | The Impact of the Financial Crisis on the Biotech and Pharma Industry | Abstract html |
| Fintan Walton | ||
| Vol 2002, No 29 (2002) | The Licensing of University Technologies | Abstract |
| Business Review Editor | ||
| Vol 2005, No 59 (2005) | The Maturing of Biotech | Details html |
| Fintan Walton | ||
| Vol 2008, No 99 (2008) | The Medicines Company Acquires Curacyte and its Lead Antithrombotic | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2013, No 2 (2013) | The Medicines Company Licenses Alnylam’s RNAi Programme Targeting PCSK9 | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 12 (2017) | The Medicines Company Sells Infectious Disease Unit | Abstract pdf html |
| Natasha Piper | ||
| Vol 2013, No 12 (2013) | The Medicines Company Steps Up Antibiotics Development with Rempex Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 1 (2013) | The Medicines Company Strengthens its Perioperative Care Franchise via Deals with Incline Therapeutics and BMS | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 96 (2008) | The Next Generation PharmaDeals | Abstract html |
| Fintan Walton | ||
| Vol 2007, No 81 (2007) | The Pharmaceutical Deals of 2006: Lessons for 2007 | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 40 (2003) | The problem with Antibiotics | Abstract |
| Business Review Editor | ||
| Vol 2008, No 102 (2008) | The Rebirth of Regenerative Medicine | Abstract html |
| Fintan Walton | ||
| Vol 2006, No 77 (2006) | The Strategy behind Galapagos' Expansion | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 92 (2008) | The Sun Rises in Japan | Abstract html |
| Fintan Walton | ||
| Vol 2005, No 62 (2005) | The Supreme Court Changes Biotech Deal Flow | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 85 (2007) | The Therapeutic Use of Cannabinoids | Abstract |
| Business Review Editor | ||
| Vol 2008, No 94 (2008) | The Times They Are A-Changing | Abstract html |
| Fintan Walton | ||
| Vol 2005, No 58 (2005) | The Value of Valuations | Details html |
| Fintan Walton | ||
| Vol 2008, No 93 (2008) | The War Dividend | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 1 (2011) | Theraclone Sciences Signs its First Major Antibody Deal with Pfizer | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 10 (2009) | Theraclone’s Influenza Antibody Alliance With Japanese Co | Abstract |
| Taskin Ahmed | ||
| Vol 2008, No 93 (2008) | Therapy Focus #8211; Melanoma Vaccines | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 94 (2008) | Therapy Focus - Type 1 Diabetes, the Latest Developments | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 58 (2005) | Therapy Focus: Acne | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 62 (2005) | Therapy Focus: Acute Myeloid Leukaemia | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 33 (2003) | Therapy Focus: Age-related Macular Degeneration | Abstract |
| Business Review Editor | ||
| Vol 2007, No 90 (2007) | Therapy Focus: Alzheimer's Disease | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 30 (2002) | Therapy Focus: Alzheimer’s Disease | Abstract |
| Business Review Editor | ||
| 2301 - 2400 of 2581 Items | << < 19 20 21 22 23 24 25 26 > >> | |